Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)

(2017) R. Maron et al.   JOURNAL OF CLINICAL ONCOLOGY

Temozolomide in malignant gliomas: current use and future targets

(2009) J. Lee Villano et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation WithMGMTPromoter Methylation Status

(2009) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

(2008) Hans Skovgaard Poulsen et al.   ACTA ONCOLOGICA

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

(2008) Felix Bokstein et al.   CANCER

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule

(2008) James R. Perry et al.   CANCER

Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults

(2008) S. Kesari et al.   CLINICAL CANCER RESEARCH

Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma

(2008) Ilse Vlassenbroeck et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

ACNU-based chemotherapy for recurrent glioma in the temozolomide era

(2008) Caroline Happold et al.   JOURNAL OF NEURO-ONCOLOGY